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a  b  s  t  r  a  c  t
The  ‘war  on  cancer’  arose  from  a toxic  combination.  A  socialite  with  powerful  friends  and  a misguided
belief  that  cancer  could  be ‘conquered’  within  7 years  recruited  a ﬂawed  US  President  to  lead  an  ‘all-out
assault  [against]  one  of  mankind’s  deadliest  and  most  elusive  enemies’.  Mary  Lasker  and  her  Citizens’
Committee  for the  Conquest  of Cancer  ran  a skilful  campaign  during  1969–1971,  comparing  the  number
of  cancer  deaths  with  American  troop  losses  in  the unpopular  Vietnam  war. Richard  Nixon  preferred  to
compare  US  cancer  mortality  with  American  troop  losses  in World  War  II.
‘Waging  war’  against  a disease  that  is so  intrinsic  to our cellular  biology  is  even  more  quixotic  than
declaring  a war  on  terror,  drugs  or religion.  ‘War’  is more  than  just  a  metaphor.  It distorts  political
thinking  about  cancer  with  the  illusory  clarity  of victory  and  defeat.  Therapeutic  attacks  on  the ‘enemy’
are prioritised  over strategies  to prevent  the disease  occurring,  and where  there  is ‘war’,  there goes  the
medical-industrial  complex.  The  therapeutic  armamentarium  has improved  out of  all recognition  since
the  1970s,  but it now  threatens  to  bankrupt  the  health  system  in  the  world’s  richest  country,  where
millions  still  await  access  to  health  insurance  under  the  Affordable  Care  Act. Elsewhere,  entire countries
have  no  access  to radiotherapy.  The  inequalities  are  glaring.One may,  perhaps,  imagine  a  world  where  an outbreak  of  sanity  has removed  injustice and  the  roots
of  terrorism.  I cannot  imagine  a  human  race  without  DNA,  which  occasionally  makes  mistakes  that  our
cells cannot  repair.  The  language  of  war,  victory  and  defeat  is  misplaced  and  outdated.  All cancer  patients,
everywhere,  deserve  prompt  and  equitable  access  to optimal  treatment  and  pain  relief.  But  we should
drop  the  lazy,  simplistic  jargon  and the distorted  priorities  of  ‘war’,  and  focus  on  prevention  to make
long-term  progress  against  cancer.
© 20Not long after the end of the most destructive war  in history,
hich had seen unprecedented developments in atomic physics
nd in the industrialisation of machinery to kill, US President Eisen-
ower used his valedictory address in 1961 to warn against the
military-industrial complex’. He suggested it could lead to more
ars, in furtherance of its own proﬁts and the maintenance of its
olitical inﬂuence: “In the councils of government, we must guard
gainst the acquisition of unwarranted inﬂuence, whether sought
r unsought, by the military-industrial complex. The potential for
he disastrous rise of misplaced power exists and will persist.” [1]
The ‘war on cancer’ can be said to have begun in 1969. On 9
ecember, the Citizens’ Committee for the Conquest of Cancer,
ed by the socialite and publicist Mary Lasker, published full-page
dvertisements in The Washington Post and The New York Times,
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entitled: “Mr. Nixon: you can cure cancer” (Fig. 1). Lasker had
an impressive record. In 1944, she had taken over the Board of
what would be renamed the American Cancer Society, increased its
income over 100-fold to $14M by 1948, and transformed it into an
agency to fund cancer research. She had argued for universal health
insurance. She had also successfully lobbied Congress for massive
increases in funding for the National Cancer Institute (NCI) by 1961
[2].
The Washington Post advertisement appeared less than ﬁve
months after the ﬁrst landing on the moon. It quoted Dr Sidney
Farber, oncologist and past president of the American Cancer Soci-
ety: “We  are so close to a cure for cancer. We  lack only the will
and the kind of money and comprehensive planning that went into
putting a man  on the moon.” The advertisement envisaged “con-
quest of cancer by America’s 200th birthday,” just 7 years later. It
was archly political, and not at all subtle. It compared the annual
number of US cancer deaths with the number of US  deaths in a
real, contemporary war that had lost a great deal of public support:
Open access under CC BY-NC-ND license.“Surely, the war against cancer has the support of 100% of the peo-
ple. It is a war in which we lost 21 times more lives last year than
we lost in Viet Nam last year. A war we can win  and put the entire
human race in our debt.” [3]
cense.
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ource: The Mary Lasker papers – http://proﬁles.nlm.nih.gov/ps/retrieve/ResourceM
This time, the US public was being invited to join a just and noble
ar – but against a disease.
The lobbying was effective. In his State of the Union address
n January 1971, US President Nixon proposed a form of univer-
al health insurance so that “no American family will be prevented
rom obtaining basic medical care by inability to pay,” as well as
etter prevention programmes. He proposed $100M for “an inten-
ive campaign to ﬁnd a cure for cancer,” adding: “The time has come
n America when the same kind of concentrated effort that split the
tom and took man  to the moon should be turned toward conquer-
ng this dread disease. Let us make a total national commitment to
chieve this goal.” [3]can cure cancer.
ata/TLBBBY.
When President Nixon signed the National Cancer Act on 23
December 1971, with the Vietnam war still ongoing, he was already
looking for his own place in history. He did not use the phrase ‘war
on cancer’ that day – perhaps because he had already declared a
‘war on narcotics’ only six months earlier [4] – but he did express
the hope that the Act would be seen by history as “the most sig-
niﬁcant action taken during this Administration.” He referred to
the “national commitment for the conquest of cancer,” made in
his State of the Union address earlier that year. His speeches were
replete with military references to “all-out assault” against “one
of mankind’s deadliest and most elusive enemies” [5]. Pointedly,
however, he chose a different war  with which to compare US cancer
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ortality, saying that “more people each year die of cancer in the
nited States than all the Americans who lost their lives in World
ar  II” [6].
In the late 1960s, however, understanding of cancer biology was
till limited, and there was outspoken resistance in the scientiﬁc
ommunity to the focus on cure. Professor Sol Spiegelman, Direc-
or of the Institute of Cancer Research at Columbia, was  one of
any who favoured basic research aimed at prevention. His acid
omment mocked the campaign: “an all-out effort at this time
to ﬁnd a cure for cancer] would be like trying to land a man  on
he moon without knowing Newton’s laws of gravity.” Spiegel-
an  also criticised the rhetoric of the ‘war on cancer’, saying it had
raised public expectations of impending breakthroughs in cancer
esearch and treatment, [that it] did not meet,” and that “by sug-
esting cancer could be ‘conquered’ within a matter of years, Lasker
had]... contributed to rising skepticism of modern biomedical sci-
nce among Americans who had long believed in its inevitable
rogress.” [2]
During the 10 years up to 2010, the annual NCI budget increased
rom $4bn to $5bn, but the proportion devoted to prevention fell
rom 11% to 7% over the same period [7].
It may  be considered unwise to declare war on terror, drugs
r religion. These are concepts, habits and beliefs, not countries
usceptible to military conquest. The ‘war on drugs’ has been widely
eemed a failure, for example, most recently by the President of
uatemala at the World Economic Forum.
It seems even more unwise to declare war on a disease, espe-
ially on cancer, a uniquely diverse constellation of diseases that
tems from spontaneous or induced errors in the complex genetic
ystems that have evolved over millions of year to regulate the
eproduction of our own cells. When we recall that the most
bvious strategy for controlling cancer is to prevent it by ﬁrst
nderstanding its causes, it may  be seen as positively absurd that
he most widely used metric of success in the war  against cancer
as been just the number of deaths, or, at best, trends in the annual
umber of deaths per 100,000 population (death rates).
The war metaphor has been all-pervasive for 40 years [8], how-
ver, so its origin is at least of passing interest [9]. In 1832, the
russian military strategist (and former child soldier) von Clause-
itz deﬁned war as “an act of force to compel our enemy to do
ur will,” and as “the continuation of policy by other means.” He
ummarised war as a triad of violence, chance and “an instrument
f policy [governed by] pure reason.” [10]
In 1996, 25 years after the National Cancer Act was  signed, one
ormer NCI director, commenting on the ﬁrst decline in overall can-
er mortality in the US, could even write [11]: “Happy birthday
War,’ you deserve a pat on the back. And you received a very nice
irthday present.” Debates on whether the ‘war’ was  being won
r lost have often been summarised with the brevity of a military
ommuniqué – we’re losing the war; we’re winning the war – leav-
ng the protagonists camped in fortiﬁed positions, with little hope
f dialogue. In the 1980s and 1990s, eminent epidemiologists such
s Bailar and Smith [12,13] and Doll [14,15] argued diametrically
pposed evaluations of progress in the ‘war against cancer’ from
ssentially the same mortality data. Like military reports, the com-
uniqués have tended to focus on body counts, and they have often
gnored a great deal of important information, such as the damage
o human lives, as well as to the economy [16–19].
Clausewitz’s deﬁnition still seems adequate to describe military
onﬂict, but it is hopelessly inadequate for public health policy for
ancer control. The ‘war against cancer’ is not a military campaign
n which the outcome is victory or defeat. ‘Victory’ against cancer
an never be so clear-cut, as if it were a war that will be won if we
re only prepared to devote enough technology or military force,
s if it were the moon landing, or the wars in Iraq and Afghanistan.
ational cancer control policy does not require ‘continuation bylicy 1 (2013) e31– e34 e33
other means’: it is simply the relentless application of evidence
and priorities to the deployment of available resources [20].
On the 40th anniversary of the National Cancer Act in 2011,
NCI Director Dr Harold Varmus explicitly discarded the metaphor
of war against cancer as inaccurate, “because cancer is a complex
group of diseases arising from fundamental aspects of our biology”
[21]. In discarding the metaphor of war, Varmus echoed the head
of the new White House Ofﬁce of National Drug Control Policy, Gil
Kerlikowske, who had immediately called for an end to the ‘war
on drugs’ on his appointment in 2009, saying that the bellicose
metaphor was a barrier to dealing with the nation’s drug issues
[22].
For both these men, charged with implementing US policy to
control two  major scourges of public health, the 40-year-old jargon
of war  is both inaccurate and counterproductive.
If politicians continue using the jaded metaphor of war against
cancer, however, the public may  come to see the ‘war’ as lost,
because millions of people world-wide will continue to be diag-
nosed with cancer each year for the foreseeable future. Many of
those patients will die from their disease. Death rates are falling
in some developed countries, but the global number of deaths will
rise, and it may  not drop below the current ﬁgure of 8 million or
so for decades to come, mainly because the world population is
increasing and ageing. In many countries outside the USA, also, the
risks of death at a given age are increasing, including from largely
preventable cancers, such as those of lung and cervix. Politicians
would be wiser to drop the simplistic military notions of winning
and losing, and to focus on making progress against cancer, step
by step [23,24], even if that seems less compelling as the message
they send to their electorates via the media.
The media also have a responsibility. Front-page stories in the
popular press on the latest breakthrough in cancer research reﬂect
the huge public appetite for good news about a disease that is still
so common, still widely feared, and still so often lethal. When such
stories appear too frequently, however, the public may  become
cynical about progress. Reporters could cut the clichés and shun
the hyperbole. They could ask instead what advantage the latest
breakthrough might bring, how many years before a new treat-
ment might be available, how many patients might be expected to
beneﬁt, and at what cost. A more nuanced approach to reporting
progress against cancer might be more informative [25].
In 1971, the ‘military-industrial complex’ was joined in the
lexicon by the ‘medical-industrial complex’ [26], deﬁning the con-
glomerate of business agencies in the healthcare system of which
the primary function is to make proﬁts, not to provide health care.
Like its military counterpart, the medical-industrial complex was
soon accused, by Dr Arnold Relman, editor of the New England
Journal of Medicine, of promoting over-use of its products and ser-
vices, increasing the risk of conﬂicts of interest for practitioners,
and exercising an undue inﬂuence on health policy [27].
The long-term impact of the medical-industrial complex has
recently been summarised in an essay by the eminent physician
Dr Bernard Lown [28], the 1985 Nobel peace laureate for his work
on International Physicians for the Prevention of Nuclear War.
In an uncanny echo of Eisenhower’s warning on the military-
industrial complex, Lown offers a mediaeval parallel about the
undue inﬂuence of corporate medical interests on national policy.
He suggests that while the Renaissance led to an escape from the
oppressive religion of the Dark Ages, a new, medical renaissance
is needed today to escape the commercialisation of health care:
“We  need to free ourselves of a similarly oppressive belief system,
the all-pervasive conviction that markets can regulate all human
interactions. These beliefs are anchored in myth and propelled by
self-interest. They have ceased to serve the public good. Central to a
market society is the stimulation of wants and artiﬁcial needs. The
result is the commoditisation of everything in sight... Doctoring has
e cer Po
n
t
p
e
s
m
S
g
r
t
s
t
u
i
t
t
t
r
p
p
C
t
t
t
t
c
a
[
m
t
a
C
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[34 M.P. Coleman / Journal of Can
ot been spared. In health care the corporate sector has discovered
he ideal commodity. Unlike other commodities, the consumer, qua
atient, can never be sated. Every aspect in the human life cycle,
very twist and turn in the aging process to the inevitable dis-
olution and death, every uncomfortable emotion, lends itself to
edicalisation. The dysfunctionality of health care in the United
tates in no small measure relates to market dominance.”
One example of this inﬂuence is provided by a research pro-
ramme  on the availability and impact of cancer drugs. This
esearch was funded and deployed by the pharmaceutical industry
o support the notion that cancer survival bears a direct relation-
hip to how quickly a given country licenses new cancer drugs for
he market, and how widely the drugs are used [29]. The report
sed a new and incorrect method of calculating survival, includ-
ng for 12 countries where the data did not exist, then correlated
he national ‘survival’ of patients diagnosed in the early 1990s with
he availability of drugs in 2002 (some of them not even licensed
ill the late 1990s) [30,31]. Despite these and other basic ﬂaws, the
eport received wide and approving publicity [32] and was cited in
arliamentary debate on policy about cancer treatment [30,33–35].
A more recent case study is provided by US President Obama’s
olicy to widen access to health insurance. The Affordable Health
are Act was challenged all the way to the Supreme Court by 26 of
he 50 states, and the health insurance lobby, ostensibly on consti-
utional grounds [36,37]. It is a shocking fact that only the failure of
hat legal challenge will now enable health insurance to be offered
o 30 million people who have none, in the richest country on earth,
urrently spending 16% of its gross domestic product on health.
Examples of inappropriate corporate inﬂuence on health policy
nd the provision of health care can be found in many countries
38]. Relman was right: we may  need to learn to live with the
edical-industrial complex, but knowing it is there may  help pro-
ect society from some of its worst excesses.
‘War on cancer’ is a simplistic metaphor that has long outlived
ny use it ever had. Politicians and the media should stop using it.
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